Molecular Partners AG
SIX:MOLN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
I
|
IFCA MSC Bhd
KLSE:IFCAMSC
|
MY |
|
Chongqing Fuling Zhacai Group Co Ltd
SZSE:002507
|
CN |
|
G
|
Gagasan Nadi Cergas Bhd
KLSE:NADIBHD
|
MY |
Molecular Partners AG
Tax Provision
Molecular Partners AG
Tax Provision Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Tax Provision | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Molecular Partners AG
SIX:MOLN
|
Tax Provision
-CHf2k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Tax Provision
-$3.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-35%
|
CAGR 10-Years
N/A
|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Tax Provision
-CHf5.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-152%
|
CAGR 10-Years
-52%
|
|
|
Idorsia Ltd
SIX:IDIA
|
Tax Provision
-CHf6.1m
|
CAGR 3-Years
8%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Tax Provision
-CHf2.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Relief Therapeutics Holding SA
SIX:RLF
|
Tax Provision
CHf2.8m
|
CAGR 3-Years
5%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
Molecular Partners AG
Glance View
Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. The company is headquartered in Schlieren, Zuerich and currently employs 163 full-time employees. The company went IPO on 2014-10-22. The firm has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
See Also
What is Molecular Partners AG's Tax Provision?
Tax Provision
-2k
CHF
Based on the financial report for Dec 31, 2025, Molecular Partners AG's Tax Provision amounts to -2k CHF.
What is Molecular Partners AG's Tax Provision growth rate?
Tax Provision CAGR 1Y
0%
Over the last year, the Tax Provision growth was 0%.
